These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7706163)

  • 41. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
    Wise R; Brenwald NP; Andrews JM; Boswell F
    J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activity of four fluoroquinolones against clinical isolates of Pseudomonas aeruginosa determined by the E test.
    Swiatlo E; Moore E; Watt J; McDaniel LS
    Int J Antimicrob Agents; 2000 Jun; 15(1):73-6. PubMed ID: 10856680
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
    Cetinkaya E; Coban AY; Durupinar B
    Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Postantibiotic effect and virulence factors depression induced by ciprofloxacin and by aminoglycosides in a clinical isolate of Pseudomonas aeruginosa.
    Hostacka A
    Zentralbl Bakteriol; 1996 Mar; 283(3):322-7. PubMed ID: 8861870
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients.
    Akaniro JC; Stutman HR; Arguedas AG; Vargas OM
    Antimicrob Agents Chemother; 1992 Feb; 36(2):255-61. PubMed ID: 1318674
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activity of 4-quinolones against Pseudomonas aeruginosa.
    Morissey I; Smith JT
    Arzneimittelforschung; 1994 Oct; 44(10):1157-61. PubMed ID: 7818593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G; Pozzetto B; Dorche G
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin.
    Kamberi M; Tsutsumi K; Kotegawa T; Kawano K; Nakamura K; Niki Y; Nakano S
    Antimicrob Agents Chemother; 1999 Mar; 43(3):525-9. PubMed ID: 10049262
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Postantibiotic effects of subinhibitory concentrations of some antibiotics and their influence on Pseudomonas aeruginosa enzymic activity.
    Hostacká A
    Folia Microbiol (Praha); 1996; 41(1):39-42. PubMed ID: 9090822
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa.
    Madaras-Kelly KJ; Larsson AJ; Rotschafer JC
    J Antimicrob Chemother; 1996 Apr; 37(4):703-10. PubMed ID: 8722536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bactericidal activity of gatifloxacin (AM-1155) against Pseudomonas aeruginosa and Enterococcus faecalis in an in vitro bladder model simulating human urinary concentrations after oral administration.
    Takahashi S; Ebisu H; Hirose T; Sano M; Nishimura M; Hirai K; Tsukamoto T; Hosaka M
    Chemotherapy; 2000; 46(2):122-8. PubMed ID: 10671763
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activity of CI-960 alone and in combination with amoxycillin against Listeria monocytogenes, and comparison with other quinolones.
    Boisivon A; Dhoyen N; Carbon C
    J Antimicrob Chemother; 1995 Sep; 36(3):527-30. PubMed ID: 8830017
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
    Wise R; Andrews JM; Brenwald N
    J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Postantibiotic effects and postantibiotic sub-MIC effects of ciprofloxacin, pefloxacin and amikacin on the biological properties of Salmonella strains.
    Majtán V; Majtánová L
    Folia Microbiol (Praha); 1997; 42(4):327-32. PubMed ID: 9449780
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
    Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
    Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
    Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
    J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa.
    Rees VE; Bulitta JB; Nation RL; Tsuji BT; Sörgel F; Landersdorfer CB
    J Antimicrob Chemother; 2015 Mar; 70(3):818-26. PubMed ID: 25381167
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A; Petersen U; Endermann R
    Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outer membrane alterations in Pseudomonas aeruginosa after five-day exposure to quinolones and carbapenems.
    Cipriani P; Giordano A; Magni A; Papa F; Filadoro F
    Drugs Exp Clin Res; 1995; 21(4):139-44. PubMed ID: 8529526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.